[Effect of anaprilin on the clinical course of stenocardia and the carbohydrate metabolic indices of ischemic heart disease patients in relation to the nature of their glucose tolerance].
Fourteen-day anaprilin treatment of coronary patients with varying glucose tolerance has demonstrated that the drug's therapeutic efficiency was greater in patients with normal glucose tolerance. Anaprilin caused a moderate drop in baseline glucose level and considerably limited the degree of hyperglycemia in response to the glucose tolerance test in coronary patients with abnormally low glucose tolerance. Insulin content was virtually unaffected by the drug, irrespective of the type of glucose tolerance.